Seeking Alpha

BioCryst Pharmaceuticals (BCRX) receives a letter from FDA which it says "outlines a pathway by...

BioCryst Pharmaceuticals (BCRX) receives a letter from FDA which it says "outlines a pathway by which an NDA [could be filed] seeking regulatory approval of intravenous permavir." Last November, shares were nearly cut in half after permavir disappointed in clinical trials. Shares +15% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|